Related Experiment Video
Updated: May 11, 2026
07:10
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
Published on: April 21, 2019
16.3K
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis
Zheng-Yi Zhou1, Mark E Bensink2, Nisha C Hazra3
1Analysis Group, Boston, MA, USA. jenny.zhou@analysisgroup.com.
Pharmacoeconomics - Open
|September 21, 2024
Summary
Health state utility values for Immunoglobulin A nephropathy (IgAN) show significant decrements with disease progression. This study quantifies quality-of-life impacts across chronic kidney disease stages, highlighting the burden of IgAN.
Area of Science:
- Nephrology
- Health Economics
- Quality of Life Research
Background:
- Immunoglobulin A nephropathy (IgAN) is a progressive kidney disease with potential for kidney failure.
- Estimating health state utility values is crucial for understanding the societal burden of IgAN.
Purpose of the Study:
- To estimate health state utility values for IgAN from a UK societal perspective.
- To quantify the impact of IgAN progression on patient quality of life.
Main Methods:
- Utilized the time trade-off (TTO) method to derive utility values.
- Developed health state vignettes describing IgAN symptoms and quality-of-life impairments.
- Collected data from 200 UK general public participants via computer-assisted telephone interviews.
Main Results:
- Mean utility values decreased with increasing chronic kidney disease (CKD) stage and proteinuria levels.
- CKD stage 5 with dialysis (0.38) and nephrotic syndrome (0.43) showed substantially lower utility values.
- Utility decrements were observed across all evaluated IgAN health states.
Conclusions:
- IgAN health states are associated with significant impairments in health status.
- Disease progression, elevated proteinuria, and nephrotic syndrome lead to substantial utility decrements.
- Findings provide valuable data for health economic evaluations of IgAN interventions.
Related Concept Videos
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:20Estimation of k and VD of Aminoglycosides
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
01:25Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...